All 20 patients who received the CAR-T in the Phase II study were MRD negative at the data cutoff, but some also had lingering neurotoxicities.

The organizations are betting they can develop a redosable genetic therapy for LMNA-related congenital muscular dystrophy that could be a cure.

Two studies presented at the meeting showed the potential of D3 Bio's next-gen KRAS (OFF) inhibitor and Revolution Medicine's novel KRAS (ON) inhibitor.

The institute said the NHS should make this combo available to patients after weighing its safety and efficacy against Tafinlar and Mekinist, the current standard treatment.

Some CLDN6-negative patients responded to the therapy, suggesting it had biomarker-agnostic potential, though the study ...

The institute backed the treatment after seeing that biliary tract cancer patients on Ziihera lived for an average 18 months, much longer than those on standard chemo can expect.

Lilly will pay $3.25 billion upfront with possible additional payments linked to the achievement of clinical, regulatory, and commercial milestones.

While the safety was more manageable, questions remain about whether the combination would best antibody-drug conjugate ...

The platform trial will add new arms testing Enhertu in solid tumors with HER2 amplification and gather data on Tafinlar-Mekinist's tissue-agnostic benefit for regular approval.

The firm will begin enrolling patients into the pivotal Part C cohort of its Phase I/II/III LIGHTHOUSE trial of ATSN-201 later this month.

The firm will use the funds to advance its KIR-CAR platform, which adapts dual receptors from NK cells to allow CAR T cells to rest when not actively targeting tumors.